Biolinerx company information, Employees & Contact Information

BioLineRx Reports Second Quarter 2025 Financial Results and Provides Corporate Update PR Newswire

BioLineRx Announces New Pilot Phase Data from Phase 2 Combination Trial of Motixafortide in First-Line Pancreatic Cancer (PDAC) to be Presented at ASCO 2025 Annual Meeting Yahoo Finance

BioLineRx Plans New Drug Pipeline Deal as Cash Runway Stretches to 2027 Stock Titan

BioLineRx Ltd. and Hemispherian AS Establish Joint Venture to Develop GLIX1, a First-in-Class, Oral, Small Molecule Targeting DNA Damage Response in Glioblastoma and Other Cancers PR Newswire

$3.8B Market Opportunity: BioLineRx's Novel Brain Cancer Drug GLIX1 Targets DNA Damage in Glioblastoma Stock Titan

BioLineRx Reports 2024 Financial Results and Provides Corporate Update PR Newswire

BioLineRx forges partnership with Norwegian biotech to advance cancer candidate Fierce Biotech

BioLineRx Announces FDA Approval of APHEXDA™ (motixafortide) in Combination MultiVu

BioLineRx Reports First Quarter 2025 Financial Results and Provides Corporate Update PR Newswire

BioLineRx: Weighing Aphexda's Breakthrough Against Financial Challenges (NASDAQ:BLRX) Seeking Alpha

H.C. Wainwright Reaffirms Buy on BioLineRx Ltd. (BLRX) After ASCO 2025 Yahoo Finance

BioLineRx, Ayrmid enter license agreement for motixafortide through Gamida Cell Yahoo Finance

BioLineRx and Ayrmid Ltd. Enter into Exclusive License Agreement to Commercialize APHEXDA® (motixafortide) through Gamida Cell Ltd. PR Newswire

BioLineRx Issues Letter to Shareholders PR Newswire

BioLineRx Announces Oral Presentation on Data from Phase 1 Clinical Trial Evaluating Motixafortide for CD34+ Hematopoietic Stem Cell Mobilization for Gene Therapies in Sickle Cell Disease at ASH 2024 PR Newswire

BioLineRx Announces Change to Ratio of American Depositary Shares to Ordinary Shares PR Newswire

BioLineRx Announces Clinical Trial Agreement with St. Jude Children's Research Hospital, Inc. to Evaluate Motixafortide for CD34+ Hematopoietic Stem Cell (HSC) Mobilization For Gene Therapy Applications in Sickle Cell Disease (SCD) PR Newswire

BioLineRx Announces $10 Million Registered Direct Offering PR Newswire

BioLineRx reports promising pancreatic cancer trial data Investing.com

Why Investors Shouldn't Be Surprised By BioLineRx Ltd.'s (TLV:BLRX) 29% Share Price Plunge simplywall.st

BioLineRx Ltd. Reports Q2 2025 Financial Results TipRanks

Jones Trading raises BioLineRx stock rating, targets $12 Investing.com

BioLineRx and Hemispherian Launch Joint Venture to Develop GLIX1 for Glioblastoma TipRanks

BioLineRx Sees Surge: Time to Invest? StocksToTrade

BioLineRx's Aphexda scores FDA nod to help myeloma patients undergo stem cell transplants Fierce Pharma

Waltham-headquartered BioLineRx gets FDA approval for cancer drug The Business Journals

BioLineRx closes license deal for motixafortide in Asia The Pharma Letter

BioLineRx Stock Jumps On Positive Data from Pilot Phase Of Pancreatic Cancer Drug Trial: Retail Cheers The ‘Buy’ Rating Stocktwits

BioLineRx Announces New Positive Results In Phase 2a Trial For Orally Available Inflammatory Bowel Disease Treatment Clinical Leader

BLRX Stock Price and Chart — TASE:BLRX TradingView

BioLineRx To Present At LD MICRO Conference; Webcast At 2:30 PM ET RTTNews

Novartis partner BioLineRx in-licenses NASH drug after joint evaluation Fierce Biotech

BioLineRx sets up Chinese JV, continuing trend for Sino-Israeli alliances Fierce Biotech

BiolineRX Shares Could Triple Barron's

BioLineRx Receives Notice of Allowance From USPTO for Patent Covering BL-1020 Drug for Treatment of Schizophrenia NBC News